BRIEF-ACADIA Pharma up in premarket after phase III pimavanserin study data

NEW YORK, March 21 Thu Mar 21, 2013 8:06am EDT

NEW YORK, March 21 (Reuters) - ACADIA Pharmaceuticals Inc : * Pharma up 6.5 percent to $7.08 in premarket after phase III pimavanserin study data

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.